Anecdotal evidence is accumulating that a particularly ominous sign on FDG-PET scans is associated with discontinuation of imatinib therapy in GIST patients. Termed a “PET flare,” it was observed by the Dana-Farber team of the [...]
Managing Progression - Clinical Management of GIST Helsinki and Barcelona 2003-Conference Highlights Charles D. Blanke, M.D., director of gastrointestinal oncology at Oregon Health and Science University (OHSU), Portland, Oregon, USA, discussed the treatment of [...]
Learn what novel patterns of GIST progression look like and mean. The majority of GIST patients treated with imatinib achieve clinical benefit, as assessed by durable complete or partial remissions or prolonged stabilization of their [...]
